Clavulanic Acid
A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.
น้ำหนักโมเลกุล
199.1600 g/mol
LogP
-1.20
TPSA
87.10 Ų
Lipinski RO5
ผ่าน
ด้านการรักษา
กลไกการออกฤทธิ์
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …
โครงสร้าง 2 มิติ
Cite this structure
Embed this structure
SMILES
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
InChI
InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1
Molecular Formula
C8H9NO5
HBD / HBA
2 / 5
พันธะที่หมุนได้
2
อะตอมหนัก
14
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Yes, Clavulanic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL777. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5280980. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="clavulanic-acid"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/clavulanic-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/clavulanic-acid/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/clavulanic-acid/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="clavulanic-acid"></drugfyi-drug>